Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Liabilities and Shareholders Equity (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Liabilities and Shareholders Equity for 12 consecutive years, with $199.1 million as the latest value for Q1 2026.

  • For Q1 2026, Liabilities and Shareholders Equity rose 3223.16% year-over-year to $199.1 million; the TTM value through Mar 2026 reached $735.1 million, up 815.31%, while the annual FY2025 figure was $240.3 million, N/A changed from the prior year.
  • Liabilities and Shareholders Equity hit $199.1 million in Q1 2026 for Crescent Biopharma, down from $240.3 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $240.3 million in Q4 2025 and bottomed at $6.0 million in Q1 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $81.2 million, with a median of $58.9 million recorded in 2022.
  • Year-over-year, Liabilities and Shareholders Equity tumbled 82.48% in 2025 and then surged 3223.16% in 2026.
  • Crescent Biopharma's Liabilities and Shareholders Equity stood at $51.8 million in 2022, then fell by 12.53% to $45.3 million in 2023, then crashed by 65.36% to $15.7 million in 2024, then soared by 1430.71% to $240.3 million in 2025, then dropped by 17.13% to $199.1 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $199.1 million, $240.3 million, and $138.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.